Rare diseases
Investigational molecules
Locations
Technetium (99MTC) pertechnetate is a radioactive diagnostic agent. It is authorised as a medicine and is used in imaging procedures to help doctors see how certain organs are working. The substance is also known as sodium pertechnetate Tc 99m injection.[2] In the clinical trial registry, it appears as a Test substance in one record, where it is given by inhalation to label another medicine so its distribution in the lungs can be measured.[1]
Technetium (99MTC) pertechnetate contains a small amount of radioactivity, which can be detected by special cameras. When it is given to a patient, the radioactivity allows doctors to see where the substance goes inside the body. In the NIMBUS study, it is used to label liposomal amphotericin B, so the amount of that medicine deposited in the lungs can be measured through single-photon emission computed tomography (SPECT/CT).[1] The FDA label states that sodium pertechnetate Tc 99m injection is a radioactive diagnostic agent used to prepare FDA-approved diagnostic radiopharmaceuticals.[2]
In the NIMBUS study, the substance is given by inhalation at a dose of 55 MBq.[1] According to the FDA label, sodium pertechnetate Tc 99m injection may also be given by intravenous injection, instilled into the urinary bladder for vesicoureteral imaging, or instilled into the eye for nasolacrimal imaging.[2] The product is produced by the RadioGenix System, a technetium Tc-99m generator, as a clear, colorless solution.[2]
There is 1 clinical trial investigating Technetium (99MTC) pertechnetate as a Test substance. The NIMBUS study is a Phase 1 interventional trial that includes 18 participants with chronic pulmonary aspergillosis.[1] The study is currently authorised, meaning it has received approval to proceed but may not yet be recruiting.[1]
The primary outcomes of the NIMBUS study include the amount of AmBisome deposited in the lungs measured through SPECT/CT, the amount of AmBisome in the lungs compared to blood concentrations, and the most appropriate dose of nebulised AmBisome based on pulmonary deposition and pharmacokinetics.[1] Pharmacokinetics describes how a medicine moves through the body over time.
The NIMBUS study is open to participants with chronic pulmonary aspergillosis. The trial plans to enrol 18 participants.[1]
The FDA label for sodium pertechnetate Tc 99m injection states that there are no contraindications, meaning no situations where the product must not be used.[2] The label includes warnings and precautions related to radiation, but no specific side effect frequencies are listed in the provided source.[2]
Beyond the NIMBUS study, technetium (99MTC) pertechnetate has been studied as a prognostic tool. A pilot clinical study of 118 Chinese patients with Graves' disease, a condition causing an overactive thyroid, found that thyroid scintigraphy using the substance before radioiodine therapy helped predict treatment outcomes. Patients with thyroid mass of 40.1 g or less, or pertechnetate uptake of 15.2% or less, had higher treatment success.[3]
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
